Customize
Quick Links
Specialties

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Celgene Corporation; Foundation Medicine, Inc; Genentech; Lilly; Loxo Oncology, Inc; Merck Sharp & Dohme Corp; and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Community Practice Connections™: 19th Annual International Lung Cancer Congress®


Release Date: October 31, 2018
Expiration Date: October 31, 2019
Media: Internet - based

Activity Overview

Community Practice Connections™: 19th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. Rapid updates from recent international conferences have also been included. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Celgene Corporation; Foundation Medicine, Inc; Genentech; Lilly; Loxo Oncology, Inc; Merck Sharp & Dohme Corp; and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Apply testing strategies to identify biomarkers that inform optimized decision making in the care of patients with lung cancer
  • Determine emerging evidence concerning the management of patients with nonmetastatic lung cancer
  • Delineate the rationale for optimized and personalized sequencing strategies utilizing clinical trial evidence, performance status, and tumor characteristics
  • Detail how recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies can be interpreted in the context of evolving paradigms in the field of lung cancer management
  • Incorporate recent data sets on single-agent and combination immunotherapeutic approaches to care for patients with lung cancer

Faculty, Staff, and Planners' Disclosures

Faculty

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Grant Research Support: AstraZeneca/Medi, Genentech; Consultant: AstraZeneca, Celgene, Genentech, Guardant Health, Lilly, Liquid Genomics

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: Grant Research Support: AstraZeneca, Eli Lilly, Merck; Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, NextCure, Novartis, Pfizer

Vassiliki Papadimitrakopoulou, MD
Professor of Medicine
Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosure: Grant Research Support: Merck, National Institutes of Health/National Cancer Institute, Bristol-Myers Squibb, Oregon Health Science Center, Cancer Prevention & Research Institute of Texas, American Association for Cancer Research; Consultant: Genentech, Merck, Bristol-Myers Squibb, Araxes Pharma, AstraZeneca

Karen L. Reckamp, MD, MS
Professor
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
 

Disclosure: Grant Research Support: To institution: ACEA, Ariad/Takeda, Bristolm-Myers Squibb, Boehringer Ingelheim, Pfizer, Xcovery, Genentech, Adaptimmune, AbbVie, Guardant, Novartis, Seattle Genetics, Loxo Oncology; Consultant: Takeda, Tesaro, Genentech

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
252627282930
Filter By